Why the study?
Vascular oxidative stress and inflammation may contribute to arterial stiffness and vascular endothelial dysfunction in CKD, but direct evidence is lacking.
Does acute infusion of ascorbic acid improve brachial artery flow-mediated dilation in patients with moderate-to-severe CKD?
Observational (n=81)
Does acute infusion of ascorbic acid improve brachial artery flow-mediated dilation in patients with moderate-to-severe CKD?
Absolute Event Rate: 3.6% vs 3.5%
p-value: p=0.04
Vascular oxidative stress and endothelial dysfunction are present in moderate-to-severe CKD but cannot be reversed by acute ascorbic acid infusion.
Acute ascorbic acid does not improve endothelial function in CKD; leaves open whether chronic therapy or other antioxidants warrant testing.
Background Increased arterial stiffness and vascular endothelial dysfunction are important nontraditional cardiovascular risk factors evident in patients with CKD. Vascular oxidative stress and inflammation may contribute to vascular dysfunction in CKD, but direct evidence is lacking. Methods We assessed carotid-femoral pulse-wave velocity (arterial stiffness) and brachial artery flow-mediated dilation (vascular endothelial function) in participants with moderate-to-severe CKD (eGFR 15–59 ml/min per 1.73 m 2 ) and in healthy controls. Change in brachial artery flow-mediated dilation after an acute infusion of ascorbic acid to inhibit vascular oxidative stress (versus saline) was also measured. Protein expression of vascular endothelial cells collected from a peripheral vein and ELISAs to assess circulating markers were also performed. Results A total of 64 participants with CKD (mean±SD, 65±8 years) and 17 healthy controls (60±5 years) were included. Carotid-femoral pulse-wave velocity was greater in participants with CKD compared with healthy controls (1071±336 versus 732±128 cm/s; P <0.001). Brachial artery flow-mediated dilation was lower in participants with CKD compared with healthy controls (3.5%±2.8% versus 5.5%±3.2%; P =0.02). Circulating inflammation markers (C-reactive protein and IL-6) were elevated in the CKD group ( P ≤0.02). Endothelial cell protein expression of NADPH (intensity versus human umbilical vein endothelial cell control, 1.48±0.28 versus 1.25±0.31; P =0.05) was greater in participants with CKD. However, ascorbic acid significantly improved brachial artery flow-mediated dilation in control participants (saline, 5.5±3.2; ascorbic acid, 6.8±3.6); as compared with participants with CKD (saline, 3.5±2.8; ascorbic acid, 3.6±3.2) (group×condition interaction P =0.04), suggesting vascular oxidative stress could not be overcome with ascorbic acid in participants with CKD. Conclusions Vascular oxidative stress is present in CKD, which cannot be overcome with acute infusion of ascorbic acid.
No takes yet. Share an insight, caveat, or question.
Nowak et al. (2020) conducted an observational in Chronic Kidney Disease (n=81). Ascorbic acid vs. Saline was evaluated on Brachial artery flow-mediated dilation (p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: